The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12 ...

The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

(IN BRIEF) Researchers from the University of Copenhagen and Rigshospitalet have made significant strides in developing a new treatment for pancreatic cancer using antibody-drug conjugates (ADCs).

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

for the antibody–drug conjugate (ADC) trastuzumab–DM1 (T–DM1). It is hoped that by coupling trastuzumab (Herceptin; Genentech/Roche) — a humanized monoclonal antibody (mAb) specific for ...

A recent study has introduced a novel class of antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (TROP2), a protein overexpressed in pancreatic ductal adenocarcinoma (PDAC), ...

World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025, with strong revenue growth through to 2035.

From local drug discovery to global innovation, economic uncertainty is taking a toll on China’s innovative biotech system, forcing local companies to weather unpredictable storms, investors said ...

Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...